IRIS
DI MARINO, PIETRO
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
NA - Nord America 298
EU - Europa 126
AS - Asia 35
Totale 459
Salva come PNG Salva come JPEG
Nazione #
US - Stati Uniti d'America 298
IE - Irlanda 65
DE - Germania 20
UA - Ucraina 15
CN - Cina 14
SG - Singapore 11
CZ - Repubblica Ceca 8
VN - Vietnam 8
BE - Belgio 6
IT - Italia 4
SE - Svezia 3
RU - Federazione Russa 2
ES - Italia 1
FR - Francia 1
IN - India 1
JP - Giappone 1
MK - Macedonia 1
Totale 459
Salva come PNG Salva come JPEG
Città #
Chandler 71
Dublin 65
Jacksonville 52
Ann Arbor 27
New York 22
Ashburn 18
Boardman 13
Beijing 10
Singapore 10
Lawrence 9
Princeton 9
Brno 8
Dong Ket 8
Munich 7
Wilmington 7
Brussels 6
Dearborn 4
Los Angeles 4
Bremen 3
Berlin 2
Dallas 2
Frankfurt am Main 1
L'aquila 1
Nizhniy Novgorod 1
Pune 1
San Francisco 1
Seattle 1
Skopje 1
Tokyo 1
Vancouver 1
Totale 366
Salva come PNG Salva come JPEG
Nome #
Evaluating the role of FAMIly history of cancer and diagnosis of multiple neoplasms in cancer patients receiving PD-1/PD-L1 checkpoint inhibitors: the multicenter FAMI-L1 study 66
Early fatigue in cancer patients receiving PD-1/PD-L1 checkpoint inhibitors: An insight from clinical practice 64
Correlations Between the Immune-related Adverse Events Spectrum and Efficacy of Anti-PD1 Immunotherapy in NSCLC Patients 58
A multicenter study of body mass index in cancer patients treated with anti-PD-1/PD-L1 immune checkpoint inhibitors: When overweight becomes favorable 54
Palliative radiotherapy in advanced cancer patients treated with immune‑checkpoint inhibitors: The PRACTICE study 54
Impact of primary tumor location in patients with RAS wild-type metastatic colon cancer treated with first-line chemotherapy plus anti-EGFR or anti-VEGF monoclonal antibodies: A retrospective multicenter study 45
Weighing the role of skeletal muscle mass and muscle density in cancer patients receiving PD-1/PD-L1 checkpoint inhibitors: a multicenter real-life study 45
Evaluation of second-line anti-VEGF after first-line anti-EGFR based therapy in RAS wild-type metastatic colorectal cancer: The multicenter “SLAVE” study 40
Late immune-related adverse events in long-term responders to PD-1/PD-L1 checkpoint inhibitors: A multicentre study 30
Post-Induction Management in Patients With Left-Sided RAS and BRAF Wild-Type Metastatic Colorectal Cancer Treated With First-Line Anti-EGFR-Based Doublet Regimens: A Multicentre Study 12
Primary versus secondary antiemetic prophylaxis with NK1 receptor antagonists in patients affected by gastrointestinal malignancies and treated with a doublet or triplet combination regimen including oxaliplatin and/or irinotecan plus fluoropyrimidines: A propensity score matched analysis 11
Totale 479
Salva come PNG Salva come JPEG
Categoria #
all - tutte 2.524
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 2.524
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2019/202057 0 0 0 0 0 0 26 2 13 6 0 10
2020/202182 4 10 0 11 9 2 12 2 13 2 9 8
2021/202236 2 0 0 4 1 1 2 2 2 2 5 15
2022/2023200 11 17 2 29 9 20 2 13 86 4 7 0
2023/202486 3 2 5 5 8 32 0 5 0 3 3 20
2024/202518 13 3 2 0 0 0 0 0 0 0 0 0
Totale 479